Literature DB >> 8877864

Characterization of metabolites of clozapine N-oxide in the rat by micro-column high performance liquid chromatography/mass spectrometry with electrospray interface.

G Lin1, G McKay, K K Midha.   

Abstract

The metabolism of clozapine N-oxide was investigated in the rat (n = 6) after a single oral dose of 20 mg kg-1. The organic extracts of rat urine were separated by conventional high performance liquid chromatography (HPLC) and individual collected fractions were analyzed by micro-column electrospray HPLC/mass spectroscopy. The compounds identified in rat urine were clozapine N-oxide, clozapine, N-desmethylclozapine, 8-deschloro-8-hydroxyclozapine, 8-deschloro-8-thiomethylclozapine, N-desmethylclozapine, 8-deschloro-8-hydroxyclozapine, 8-deschloro-8-thiomethylclozapine, N-desmethyl-8-deschloro-8-thiomethylclozapine and 8-deschloro-8-methylsulfinylclozapine. With the exception of the unchanged clozapine N-oxide, no other metabolite containing a N-oxide functional group could be found, the concentrations of clozapine N-oxide, clozapine and N-desmethylclozapine excreted from rat urine were determined utilizing a conventional HPLC procedure with UV detection. The recoveries of these three analytes reported as the percentage of the dosage from the 0.24 h urine are 0.93 +/- 0.54%, 0.06 +/- 0.03% and 0.01 +/- 0.006% respectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877864     DOI: 10.1016/0731-7085(96)01738-4

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  9 in total

1.  Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.

Authors:  Juan L Gomez; Jordi Bonaventura; Wojciech Lesniak; William B Mathews; Polina Sysa-Shah; Lionel A Rodriguez; Randall J Ellis; Christopher T Richie; Brandon K Harvey; Robert F Dannals; Martin G Pomper; Antonello Bonci; Michael Michaelides
Journal:  Science       Date:  2017-08-04       Impact factor: 47.728

2.  Dose-dependent reduction in cocaine-induced locomotion by Clozapine-N-Oxide in rats with a history of cocaine self-administration.

Authors:  Yasmin Padovan-Hernandez; Lori A Knackstedt
Journal:  Neurosci Lett       Date:  2018-03-20       Impact factor: 3.046

Review 3.  Applications of optogenetic and chemogenetic methods to seizure circuits: Where to go next?

Authors:  Patrick A Forcelli
Journal:  J Neurosci Res       Date:  2017-08-09       Impact factor: 4.164

4.  Remifentanil self-administration in mice promotes sex-specific prefrontal cortex dysfunction underlying deficits in cognitive flexibility.

Authors:  Eden M Anderson; Annabel Engelhardt; Skyler Demis; Elissa Porath; Matthew C Hearing
Journal:  Neuropsychopharmacology       Date:  2021-05-19       Impact factor: 8.294

5.  The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice.

Authors:  Daniel F Manvich; Kevin A Webster; Stephanie L Foster; Martilias S Farrell; James C Ritchie; Joseph H Porter; David Weinshenker
Journal:  Sci Rep       Date:  2018-03-01       Impact factor: 4.379

6.  DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo.

Authors:  Karen J Thompson; Elham Khajehali; Sophie J Bradley; Jovana S Navarrete; Xi Ping Huang; Samuel Slocum; Jian Jin; Jing Liu; Yan Xiong; Reid H J Olsen; Jeffrey F Diberto; Kristen M Boyt; Melanie M Pina; Dipanwita Pati; Colin Molloy; Christoffer Bundgaard; Patrick M Sexton; Thomas L Kash; Michael J Krashes; Arthur Christopoulos; Bryan L Roth; Andrew B Tobin
Journal:  ACS Pharmacol Transl Sci       Date:  2018-07-27

7.  Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice.

Authors:  Martin Jendryka; Monika Palchaudhuri; Daniel Ursu; Bastiaan van der Veen; Birgit Liss; Dennis Kätzel; Wiebke Nissen; Anton Pekcec
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

8.  Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments.

Authors:  Duncan A A MacLaren; Richard W Browne; Jessica K Shaw; Sandhya Krishnan Radhakrishnan; Prachi Khare; Rodrigo A España; Stewart D Clark
Journal:  eNeuro       Date:  2016-11-01

9.  Gram scale preparation of clozapine N-oxide (CNO), a synthetic small molecule actuator for muscarinic acetylcholine DREADDs.

Authors:  Phillip L van der Peet; Christian Gunawan; Alaa Abdul-Ridha; Sherie Ma; Daniel J Scott; Andrew L Gundlach; Ross A D Bathgate; Jonathan M White; Spencer J Williams
Journal:  MethodsX       Date:  2018-03-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.